These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1046 related articles for article (PubMed ID: 26759368)

  • 1. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR
    Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
    Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
    Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
    Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.
    Baeuerle PA; Ding J; Patel E; Thorausch N; Horton H; Gierut J; Scarfo I; Choudhary R; Kiner O; Krishnamurthy J; Le B; Morath A; Baldeviano GC; Quinn J; Tavares P; Wei Q; Weiler S; Maus MV; Getts D; Schamel WW; Hofmeister R
    Nat Commun; 2019 May; 10(1):2087. PubMed ID: 31064990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 20. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.